Artelo Biosciences, Inc. Releases 2025 Audited Financial Statements: Significant Developments and Ongoing Risks for Investors

Key Financial Highlights for 2025

• Net Loss Continues to Widen: Artelo Biosciences reported a net loss of \$12.88 million for the year ended December 31, 2025, compared to a net loss of \$9.83 million in 2024. The company has accumulated an overall deficit of \$63.02 million.
• Declining Cash Position: Cash and cash equivalents dropped dramatically to \$0.6 million from \$2.34 million a year prior, raising concerns about short-term liquidity.
• Operating Expenses: Total operating expenses increased to \$11.40 million in 2025 (from \$10.11 million in 2024), driven primarily by higher general and administrative costs (\$5.98 million) and sustained research and development expenses (\$5.42 million).
• Negative Working Capital and Stockholders’ Equity: The company ended the year with negative stockholders’ equity of \$1.27 million, a reversal from positive equity of \$2.86 million in 2024. Current liabilities (\$4.04 million) now greatly exceed current assets (\$0.70 million).

Going Concern Warning

Artelo’s auditors have reiterated a going concern warning. The company’s recurring operating losses, negative working capital, and the need for additional funding raise substantial doubt about its ability to continue as a going concern over the next 12 months. Management’s plans include additional equity or debt offerings, but there is no assurance of success. The financial statements do not include adjustments that may result from the outcome of this uncertainty.

Capital Raises and Corporate Actions in 2025

• Convertible Notes Issued: In May 2025, Artelo raised \$900,000 via unsecured convertible notes bearing 12% interest. Notably, \$350,000 of these were acquired by insiders (directors, an officer, and consultants). Upon maturity, \$692,000 of notes, including \$195,000 from related parties, were converted into new notes and warrants. The company realized a \$1.16 million loss on extinguishment of these debts.
• Equity Offerings:
  • Private Placement (June 2025): \$1.43 million gross (\$1.08 million net) raised through a mix of shares and pre-funded warrants.
  • ATM Program (July 2025): Artelo entered an At-The-Market (ATM) agreement with R.F. Lafferty to sell up to \$6.5 million in shares. In 2025, only \$442,000 was raised.
  • Underwritten Offerings (September 2025): Two underwritten offerings raised \$2.93 million net. The first offering (September 4) raised \$2.69 million net, including an over-allotment. The second (September 30) raised \$1.76 million net. Both involved a combination of shares and pre-funded warrants.
• PIPE Transaction Attempted and Cancelled: In August 2025, Artelo initiated a \$9.48 million at-the-market PIPE to be used for purchasing Solana (SOL) cryptocurrency. This transaction was mutually terminated, and proceeds were returned.
• Reverse Stock Splits: On June 13, 2025, a 1-for-6 reverse split was executed, reducing outstanding shares from 3.28 million to approximately 547,000. On March 10, 2026, a subsequent 3:1 reverse split was completed. The number of authorized shares was increased to 500 million following shareholder approval.

Other Noteworthy Developments

• Digital Asset Investment: Artelo invested \$250,000 in Solana (SOL) tokens in 2025, which was fully divested before year-end, resulting in a realized loss of \$62,000.
• Intangible Asset: The company maintains an intangible asset valued at \$2.04 million, related to the exclusive license for ART27.13, with no impairment recognized.
• Options and Warrants Issuance:
  • In 2025, the company granted 32,963 options (valued at \$849,000) and issued 507,403 warrants, bringing outstanding warrants to 466,263 with a weighted average exercise price of \$16.89. All warrants are currently exercisable.
  • Stock-based compensation expense reached \$1.14 million in 2025.

Material Events After Year-End

• Equity Purchase Agreement (January 30, 2026): Artelo entered an agreement with Square Gate Capital to sell up to \$25 million of common stock, with an option to increase to \$50 million. As consideration, Square Gate received 35,342 shares and 62,124 pre-funded warrants, valued at \$500,000, plus up to \$35,000 in expenses. The agreement restricts Artelo from engaging in other variable-rate transactions without Square Gate’s permission, except for ATM offerings.
• Reverse Stock Split (March 10, 2026): A 3:1 reverse split was executed, impacting both common and preferred stock. All share, option, and warrant figures in the financials have been adjusted to reflect this.

Risks and Price-Sensitive Issues for Shareholders

• Liquidity and Solvency Concerns: The company’s cash burn, negative equity, and large accumulated deficit make future funding highly uncertain. Inability to raise capital could lead to severe dilution, asset liquidation, or bankruptcy.
• Frequent Dilution: Multiple capital raises, reverse splits, and large increases in authorized shares may severely dilute existing shareholders.
• Uncertain Business Model: The failed attempt to invest in cryptocurrency (Solana) and the absence of revenues highlight ongoing strategic risks.
• Insider Participation in Financing: Directors, officers, and consultants participated in convertible note financings, which may raise governance and related-party transaction concerns.
• Going Concern Warning: The auditor’s warning is material and price-sensitive, as it signals significant doubts about the company’s ability to operate over the next 12 months.

Summary for Investors

Artelo Biosciences remains a high-risk, clinical-stage biotech with no revenue, a rapidly diminishing cash balance, ongoing losses, and an urgent need for new financing. While the company has demonstrated an ability to raise capital through a variety of instruments, this has come at the cost of significant dilution and financial engineering, including multiple reverse stock splits. The repeated going concern warnings, insider participation in financings, and failed strategic initiatives (such as the now-cancelled Solana investment) should all be carefully considered by current and prospective shareholders.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with a financial advisor before making investment decisions. The information herein is based on company filings and may be subject to change.

View ARTELO BIOSCIENCES, INC. Historical chart here